External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology 2024 ASCO Annual Meeting
Roche and Genentech at

2024 ASCO Annual Meeting

May 31 - June 04
Chicago USA/Virtual (Hybrid)
am.asco.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
08:00 PM
Duration 180mins Chicago, USA
First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2 negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses
Juric D, Kalinsky K, Turner N, Jhaveri K, Schmid P, Loi S, Saura C, Im SA, Sunpaweravong P, Li H, Musolino A, Zhang Q, Nowecki Z, Leung R, Thanopoulou E, Shankar N, Lei G, Devine J, Stout T, Loibl S
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 3hrs Chicago USA
Interim analysis (IA) of the giredestrant (G) + everolimus (EVERO) arm in MORPHEUS Breast Cancer (BC): A Phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Wander S, Stemmer S, Rugo H, Im S, Lau P, Paluch-Shimon S, Cahuzac C, Collier A, Shah M, Ngo H, Schwab R, Zhu J, Oliveria M
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.